Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Food Labeling; Notification Procedures for Statements on Dietary Supplements, 39736 [2013-15794]
Download as PDF
39736
Federal Register / Vol. 78, No. 127 / Tuesday, July 2, 2013 / Notices
The burden estimate for this reporting
requirement was derived in our Office
of Minor Use and Minor Species Animal
Drug Development by extrapolating the
current investigational new animal
drug/new animal drug application
reporting requirements for similar
actions by this same segment of the
regulated industry and from previous
interactions with the minor use/minor
species community.
Dated: June 25, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
Dated: June 26, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–15794 Filed 7–1–13; 8:45 am]
Food and Drug Administration
BILLING CODE 4160–01–P
[Docket No. FDA–2013–D–0576]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Draft Guidance for Industry:
Considerations for the Design of EarlyPhase Clinical Trials of Cellular and
Gene Therapy Products; Availability
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
AGENCY:
[Docket No. FDA–2013–N–0032]
HHS.
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Food Labeling; Notification
Procedures for Statements on Dietary
Supplements
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Food Labeling; Notification Procedures
for Statements on Dietary Supplements’’
has been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On March
27, 2013, the Agency submitted a
proposed collection of information
entitled ‘‘Food Labeling; Notification
Procedures for Statements on Dietary
Supplements’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0331. The
approval expires on May 31, 2016. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
SUMMARY:
tkelley on DSK3SPTVN1PROD with NOTICES
ACTION:
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Establishing and Maintaining a List of
U.S. Dairy Product Manufacturers/
Processors With Interest in Exporting
to Chile
BILLING CODE 4160–01–P
VerDate Mar<15>2010
16:48 Jul 01, 2013
Jkt 229001
ACTION:
Food and Drug Administration,
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Establishing and Maintaining a List of
U.S. Dairy Product Manufacturers/
Processors With Interest in Exporting to
Chile’’ has been approved by the Office
of Management and Budget (OMB)
under the Paperwork Reduction Act of
1995.
FOR FURTHER INFORMATION CONTACT:
Domini Bean, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On March
25, 2013, the Agency submitted a
proposed collection of information
entitled, ‘‘Establishing and Maintaining
a List of U.S. Dairy Product
Manufacturers/Processors With Interest
in Exporting to Chile’’ to OMB for
review and clearance under 44 U.S.C.
3507. An Agency may not conduct or
sponsor, and a person is not required to
respond to, a collection of information
unless it displays a currently valid OMB
control number. OMB has now
approved the information collection and
has assigned OMB control number
0910–0509. The approval expires on
May 31, 2016. A copy of the supporting
statement for this information collection
is available on the Internet at https://
www.reginfo.gov/public/do/PRAMain.
SUMMARY:
Dated: June 26, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013–15796 Filed 7–1–13; 8:45 am]
BILLING CODE 4160–01–P
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
AGENCY:
Food and Drug Administration,
HHS.
[Docket No. FDA–2012–N–1106]
[FR Doc. 2013–15792 Filed 7–1–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance
document entitled ‘‘Guidance for
Industry: Considerations for the Design
of Early-Phase Clinical Trials of Cellular
and Gene Therapy Products’’ dated July
2013. The draft guidance document
provides sponsors of Investigational
New Drug Applications (INDs) for
cellular therapy (CT) and gene therapy
(GT) products (referred to collectively as
CGT products) with recommendations
to assist in designing early-phase
clinical trials of CGT products.
DATES: Although you can comment on
any guidance at any time (see 21 CFR
10.115(g)(5)), to ensure that the Agency
considers your comment on this draft
guidance before it begins work on the
final version of the guidance, submit
either electronic or written comments
on the draft guidance by November 22,
2013.
ADDRESSES: Submit written requests for
single copies of the draft guidance to the
Office of Communication, Outreach and
Development (HFM–40), Center for
Biologics Evaluation and Research
(CBER), Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852–1448. Send one
self-addressed adhesive label to assist
the office in processing your requests.
The draft guidance may also be obtained
by mail by calling CBER at 1–800–835–
4709 or 301–827–1800. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the draft guidance
document.
Submit electronic comments on the
draft guidance to https://
www.regulations.gov. Submit written
comments to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Melissa Reisman, Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, suite 200N, Rockville,
MD 20852–1448, 301–827–6210.
SUMMARY:
E:\FR\FM\02JYN1.SGM
02JYN1
Agencies
[Federal Register Volume 78, Number 127 (Tuesday, July 2, 2013)]
[Notices]
[Page 39736]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-15794]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0032]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Food Labeling; Notification
Procedures for Statements on Dietary Supplements
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Food Labeling; Notification
Procedures for Statements on Dietary Supplements'' has been approved by
the Office of Management and Budget (OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT: Domini Bean, Office of Information
Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B,
Rockville, MD 20850, 301-796-5733, domini.bean@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On March 27, 2013, the Agency submitted a
proposed collection of information entitled ``Food Labeling;
Notification Procedures for Statements on Dietary Supplements'' to OMB
for review and clearance under 44 U.S.C. 3507. An Agency may not
conduct or sponsor, and a person is not required to respond to, a
collection of information unless it displays a currently valid OMB
control number. OMB has now approved the information collection and has
assigned OMB control number 0910-0331. The approval expires on May 31,
2016. A copy of the supporting statement for this information
collection is available on the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: June 26, 2013.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2013-15794 Filed 7-1-13; 8:45 am]
BILLING CODE 4160-01-P